March 2026—Labcorp has expanded its molecular residual disease portfolio to include Labcorp Plasma Detect ID, a whole exome sequence–guided, personalized panel for patients with stages I–III breast cancer or stages I–IIIA non-small cell lung cancer, and Plasma Detect Genome, a whole genome MRD test for stage III colon cancer. Labcorp reports that its Plasma Detect ID and Plasma Detect Genome MRD tests can detect ctDNA down to a limit of detection of 0.005 percent.
Labcorp, 336-229-1127